Ascendis Pharma A/S Weighted Average Exercise Price Of Other Equity Instruments Outstanding In Share-based Payment Arrangement2019
Ascendis Pharma A/S (ASND) had Weighted Average Exercise Price Of Other Equity Instruments Outstanding In Share-based Payment Arrangement2019 of 103.24 EUR/shares as of 2025-12-31, per its 20-F filed 2026-02-11.
Financial Statements › Notes › Compensation Related Costs
ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019 · last filed 2026-02-11
- 2019-12-31: Weighted Average Exercise Price Of Other Equity Instruments Outstanding In Share-based Payment Arrangement2019 46.36 EUR.
EUR
| Period end | Weighted Average Exercise Price Of Other Equity Instruments Outstanding In Share-based Payment Arrangement2019 |
|---|---|
| 2019-12-31 | 46.36 EUR 20-F · filed 2020-04-03 |
EUR/shares
| Period end | Weighted Average Exercise Price Of Other Equity Instruments Outstanding In Share-based Payment Arrangement2019 |
|---|---|
| 2025-12-31 | 103.24 EUR/shares 20-F · filed 2026-02-11 |
| 2024-12-31 | 93.25 EUR/shares 20-F · filed 2026-02-11 |
| 2023-12-31 | 86.38 EUR/shares 20-F · filed 2026-02-11 |
| 2022-12-31 | 81.30 EUR/shares 20-F · filed 2026-02-11 |
| 2021-12-31 | 80.30 EUR/shares 20-F · filed 2022-03-02 |
| 2019-12-31 | 46.36 EUR/shares 20-F · filed 2020-04-03 |